CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $606.04M, above the global median of $548.88M
- FinancialsAltman Z-Score 1.66: grey zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.05%
Annual Rate
KRW 410.00Paid annual
Payout Ratio
13.5%Sustainable
Payback Period
97.9 yr
Last Ex-Dividend
Mar 30, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.10TKRW797.49M · vs all stocks (USD)
Trailing P/E
14.60xRevenue (TTM)
839.63BKRW606.04M · vs all stocks (USD)
Profit Margin
5.34%Beta
0.5810xvs all stocks
52-Week Change
-18.15%vs all stocks
Market Capitalization
1.10TKRW797.49M · vs all stocks (USD)
Enterprise Value
1.43TKRW1.03B · vs all stocks (USD)
Trailing P/E
14.60xForward P/E
9.74xPEG Ratio
1.07xPrice to Sales (TTM)
1.32xPrice to Book (MRQ)
0.8174xEnterprise to Revenue
1.70xEnterprise to EBITDA
14.98xGross Margin
44.69%Profit Margin
5.34%Operating Margin
11.23%Return on Assets (TTM)
2.11%Return on Equity (TTM)
3.90%Revenue (TTM)
839.63BKRW606.04M · vs all stocks (USD)
Revenue per Share (TTM)
29.38KKRWUpdated Sep 20, 2026Quarterly Revenue Growth
5.10%Gross Profit (TTM)
348.18BKRW251.32M · vs all stocks (USD)
EBITDA (TTM)
125.25BKRW90.40M · vs all stocks (USD)
Net Income (TTM)
41.49BKRW29.95M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
80.70%Operating Cash Flow (TTM)
42.61BKRW30.76M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-6.63BKRW-4.78M · vs all stocks (USD)
Trailing Annual Dividend Rate
410.00KRWUpdated Sep 20, 2026Trailing Annual Dividend Yield
1.05%vs all stocks
Payout Ratio
13.53%Revenue
1.06TKRWFY2025 · Dec 31, 2025Cost of Goods Sold
575.51BKRWFY2025 · Dec 31, 2025Gross Profit
487.64BKRWFY2025 · Dec 31, 2025Operating Income
110.88BKRW80.03M · vs all stocks (USD)
Pre-tax Income
91.32BKRWFY2025 · Dec 31, 2025Income Tax Expense
15.62BKRWFY2025 · Dec 31, 2025Net Income
75.70BKRWFY2025 · Dec 31, 2025EBIT
106.95BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
157.70BKRWFY2025 · Dec 31, 2025Research & Development
24.80BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
200.10BKRWFY2025 · Dec 31, 2025Other Operating Expenses
5.77BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
2.76BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
15.63BKRWFY2025 · Dec 31, 2025EPS (Basic)
2.67KKRWFY2025 · Dec 31, 2025EPS (Diluted)
2.67KKRWFY2025 · Dec 31, 2025Basic Shares Outstanding
28.33MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
28.33MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
75.70BKRWFY2025 · Dec 31, 2025Operating Cash Flow
73.87BKRWFY2025 · Dec 31, 2025Free Cash Flow
-391.24MKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
91.41BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
75.70BKRWFY2025 · Dec 31, 2025Other Non-cash Items
12.87BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-21.43BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
6.74BKRWFY2025 · Dec 31, 2025Capital Expenditures
-74.26BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-11.79BKRWFY2025 · Dec 31, 2025Net Acquisitions
-3.96BKRWFY2025 · Dec 31, 2025Purchase of Investments
-778.62BKRWFY2025 · Dec 31, 2025Sale of Investments
694.78BKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-162.06BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
395.00BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-310.00BKRWFY2025 · Dec 31, 2025Common Dividends Paid
-9.92BKRWFY2025 · Dec 31, 2025Other Financing Charges
6.05MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
75.09BKRWFY2025 · Dec 31, 2025Shares Outstanding
28.33MSharesUpdated Sep 20, 2026Float Shares
15.03MSharesUpdated Sep 20, 2026% Held by Insiders
46.95%vs all stocks
% Held by Institutions
15.85%vs all stocks
Total Cash (MRQ)
136.45BKRW98.49M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.82KKRWUpdated Sep 20, 2026Total Debt (MRQ)
460.06BKRW332.07M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3975xCurrent Ratio (MRQ)
1.13xBook Value per Share (MRQ)
47.71KKRWUpdated Sep 20, 2026Total Assets
2.10TKRW1.51B · vs all stocks (USD)
Total Current Assets
486.31BKRWFY2025 · Dec 31, 2025Total Liabilities
768.53BKRWFY2025 · Dec 31, 2025Total Non-current Assets
1.61TKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
175.95BKRWFY2025 · Dec 31, 2025Total Current Liabilities
592.58BKRWFY2025 · Dec 31, 2025Cash
91.41BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
91.41BKRWFY2025 · Dec 31, 2025Other Short-term Investments
68.16BKRWFY2025 · Dec 31, 2025Accounts Receivable
139.38BKRWFY2025 · Dec 31, 2025Inventory
168.14BKRWFY2025 · Dec 31, 2025Accounts Payable
87.39BKRWFY2025 · Dec 31, 2025Short-term Debt
362.76BKRWFY2025 · Dec 31, 2025Other Current Liabilities
3.17BKRWFY2025 · Dec 31, 2025Long-term Debt
159.58BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
2.25BKRWFY2025 · Dec 31, 2025Common Stock (Book)
14.45BKRWFY2025 · Dec 31, 2025Retained Earnings
274.83BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
1.33TKRW958.84M · vs all stocks (USD)
52-Week Low
34.80KKRWUpdated Sep 20, 202652-Week High
58.60KKRWUpdated Sep 20, 202652-Week Change
-18.15%vs all stocks
Beta
0.5810xvs all stocks
50-Day MA
40.26KKRWUpdated Sep 20, 2026200-Day MA
47.10KKRWUpdated Sep 20, 2026Avg 10-Day Volume
95.50KSharesUpdated Sep 20, 2026Avg 30-Day Volume
120.07KSharesUpdated Sep 20, 2026Diluted EPS (TTM)
2.67KKRWUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.45Profit Margin: 0.05
Financial Health
Altman Z-Score 1.66: grey zoneSignificant
Altman Z-Score: 1.66
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $606.04M, above the global median of $548.88MNotable
Revenue (USD): 606,042,518.638Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
4D Molecular Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jacobio Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lexicon Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengda Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanxi Zhendong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Shanghai Kaibao Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Chunlizhengda Medical Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule